

## AMENDMENT

Serial No. 08/454,529  
Atty. Docket No. GP004-16.DV4Remarks

Claims 486-560, 563-582, 585-592, 595-618 and 621-630 are presently pending in the subject application.

Reconsideration and allowance are respectfully requested in view of the above amendments and the following remarks.

Claims 583, 584, 593, 594, 619 and 620 are canceled herein without prejudice to the prosecution of the subject matter of these claims in this or a future continuing application.

Claims 486-491 have each been amended herein to recite that the variable region is present in an rRNA or rDNA sequence in a location corresponding to a target region "consisting of or is contained within" one of the listed target regions. This amendment is consistent with the recitation of narrower target regions in the dependent claims (*see* claims 494, 495, 500-503, 506-509, 514-517, 533-546, 549-560, 565-582, 585-588, 591, 592, 595-600, 605-610, 613-618 and 621-630). Because the narrower target regions recited in the dependent claims are not newly added, it is believed that the amended language of the independent claims does not raise new issues requiring a further search.

Claims 488 and 489 have been amended herein to recite a target region corresponding to bases "600-670" instead of "600-675" of *E. coli* 16S rRNA or the encoding DNA. This amendment is consistent with originally filed claim 310 and the language of dependent claims 502 and 503 herein.

Claims 488 and 489 have been also amended herein to recite a target region corresponding to bases "980-1050" instead of "975-1060" of *E. coli* 16S rRNA or the encoding DNA. This amendment is consistent with originally filed claim 314 and the language of dependent claims 508 and 509 herein.

Claims 490 and 491 have been amended herein consistent with the unamended language of dependent claims 621, 622, 627 and 628 to recite that the target region corresponding to bases "1440-1600" of *E. coli* 23S rRNA or the encoding DNA is, instead, bases "1440-1620" of *E. coli* 23S rRNA or the encoding DNA. (This amendment is further supported by original claims

**AMENDMENT**Serial No. 08/454,529  
Atty. Docket No. GP004-16.DV4

64 and 82 and Examples 8 and 10 of the specification.) Thus, this amendment to claims 490 and 491 does not introduce new matter nor does it raise new issues requiring a further search.

Claims 539 and 540 have been amended herein to recite a target region corresponding to bases "450-490" instead of "405-490" of *E. coli* 16S rRNA or the encoding DNA. This amendment is consistent with originally filed claim 95 and Example 9 of the specification.

Claims 555 and 556 have been amended herein to recite a target region corresponding to bases "980-1030" instead of "980-1050" of *E. coli* 16S rRNA or the encoding DNA. This amendment is consistent with originally filed claims 216 and 272 and Examples 18 and 21 of the specification.

Claims 577 and 578 have been amended herein to recite a target region corresponding to bases "1155-1190" instead of "1150-1200" of *E. coli* 23S rRNA or the encoding DNA. This amendment is consistent with originally filed claims 64 and 149 and Example 4 of the specification.

Claims 613 and 614 have been amended herein to recite a target region corresponding to bases "335-395" instead of "270-395" of *E. coli* 23S rRNA or the encoding DNA. This amendment is consistent with originally filed claims 117 and 209 and Examples 10 and 17 of the specification.

The claims are further amended herein to make non-substantive editorial changes and to address the Examiner's rejections in the manner described below.

**Interview Summary**

Applicants wish to thank the Examiner for granting the undersigned a telephonic interview on August 31, 2005. The issues discussed with the Examiner are fully reflected in the above amendments to the claims and in the responses to the Examiner's rejections set forth below.

**Rejections Under 35 U.S.C. § 112, First Paragraph**

Claims 486, 487, 512, 513, 528 and 529 stand rejected by the Examiner under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. Applicants submit that this rejection is rendered moot by amendments to the claims herein, which

## AMENDMENT

Serial No. 08/454,529  
Atty. Docket No. GP004-16.DV4

provide that when the target region corresponds to bases 1255-1290 of *E. coli* 16S rRNA or the encoding DNA, then *M. pneumoniae* is the target species and the non-target species include *M. genitalium*. This amendment finds support in the specification at page 58, line 6 *et seq.*, which discloses four probes targeting this region that are specific for *M. pneumoniae*. As shown in Tables 27 and 28 of the specification, the *M. pneumoniae* probes do not cross-react with other respiratory pathogens, including *M. genitalium*. This property of the probes is significant because *M. pneumoniae* and *M. genitalium* are known to share significant homology. See abstract of Attachment A, Jensen *et al.* (2003) *J. Clin. Microbiol.* 41, 261-266 ("*M. genitalium* showed the most-prominent homology to the *M. pneumoniae* 16S rRNA sequence of *M. pneumoniae* (98% homology).") And, in U.S. Patent No. 5,851,767 ("the '767 patent"), Standbridge *et al.* do not disclose that all or any portion of the claimed target region could be useful for distinguishing *M. pneumoniae* over *M. genitalium*, but instead disclose fragments that differ significantly from the 16S rRNA gene of *E. coli* and which form the bases for mycoplasma-specific probes. See the '767 patent at column 2, lines 15-20.

Claims 486 and 487 stand rejected by the Examiner under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. In support of this rejection, the Examiner correctly notes that the recitation of a target region corresponding to bases 65-108 of *E. coli* "16S rRNA" or the encoding DNA in the proviso language should have been a reference to "5S rRNA." In response, Applicants have amended claims 486 and 487 to correct this obvious error.

For the reasons set forth above, Applicants submit that the amended claim language complies with the written description requirement and does not introduce new matter or raise new issues requiring a further search. Accordingly, withdrawal of these rejections is hereby respectfully requested.

AMENDMENT

Serial No. 08/454,529  
Atty. Docket No. GP004-16.DV4Rejection Under 35 U.S.C. § 112, Second Paragraph

Claims 508, 509, 512, 513, 528 and 529 stand rejected by the Examiner under 35 U.S.C. § 112, second paragraph, as being indefinite. In particular, the Examiner takes the position that the these claims depend, either directly or indirectly, from claims which recite overlapping but not identical base ranges. In an effort solely intended to advance the prosecution of this application, Applicants have amended claim 508 herein to depend from claims 486-489 in the alternative. Claims 512 and 513 have been amended herein to recite that the target region is in a location corresponding to bases "1255-1290" instead of bases "1250-1290" of *E. coli* 16S rRNA or the encoding DNA. And, although not addressed by the Examiner, claims 498 and 500 have been amended to depend from claims 488-491 in the alternative. Additionally, the rejection of claims 528 and 529 is believed to be rendered moot by Applicants amendments to claims 486 and 487 herein, which correct the proviso language to indicate that bases 65-108 represent a region of *E. coli* "5S" rather than "16S" rRNA or the encoding DNA. Accordingly, Applicants submit that the claims are definite and withdrawal of this rejection is respectfully requested.

Rejection Under 35 U.S.C. § 102

Claims 488, 489, 508, 509, 512 and 513 stand rejected by the Examiner under 35 U.S.C. § 102(e) as being anticipated by Stanbridge *et al.* (U.S. Patent No. 5,851,767). In support of this rejection, the Examiner contends that these claims recite a target region (*i.e.*, a location corresponding to bases 1255-1290 of *E. coli* 16S rRNA or the encoding DNA) which contains a base section of 16S rRNA disclosed by Stanbridge as forming the basis for a mycoplasma probe without introducing any limitation on what is detected, as in claims 486 and 487. Claims 488, 489 and their dependents, however, require that the recited hybridization assay means or oligonucleotide probe distinguish between nucleic acid of at least one target species and nucleic acid of at least one non-target species belonging to the same genus as the target species. Since Stanbridge merely discloses 16S rRNA gene fragments that differ from the 16S rRNA gene of *E. coli*, and nowhere discloses or

AMENDMENT

Serial No. 08/454,529  
Atty. Docket No. GP004-16.DV4

suggests that these fragments might be used to distinguish between species of mycoplasma (*see Stanbridge at col. 2, lines 15-30*), Applicants submit that the claims are patentable in view of Stanbridge. Accordingly, withdrawal of this rejection is respectfully requested.

Claim Objections

Claims 492-507, 510, 511, 514-527, 530-560 and 563-592 stand objected to by the Examiner has being dependent upon a rejected base claim. Because Applicants believe that the indicated claims should be allowable for the reasons set forth above, Applicants respectfully decline the Examiner's invitation to rewrite the objected to claims in independent form, including all of the limitations of the base claim and any intervening claims, at this time.

Allowed Claims

Applicants note with appreciation that claims 490, 491 and 593-630 are allowed.

Conclusion

Applicants submit that the subject application is in condition for allowance and early notice to that effect is earnestly solicited.

No fee is believed due in connection with this Amendment. If Applicants are mistaken, then please charge the amount due to Deposit Account No. 07-0835 in the name of Gen-Probe Incorporated.


AMENDMENT

Serial No. 08/454,529  
Atty. Docket No. GP004-16.DV4

Certificate of Transmission

I hereby certify that this correspondence (and any referred to as attached or enclosed) is being sent by facsimile to 571-273-8300 on the date indicated below to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Respectfully submitted,



By:

Charles B. Cappellari  
Registration No. 40,937  
Attorney for Applicants

Date: September 1, 2005

GEN-PROBE INCORPORATED  
Patent Department  
10210 Genetic Center Drive  
San Diego, California 92121  
PH: 858-410-8927  
FAX: 858-410-8928

SEP-01-2005 07:57PM FROM-Gen-Probe Incorporated - Patent Dept. +1 858 410 8928 T-721 P.035/041 F-004

**ATTACHMENT A**

JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2003, p. 261–266  
 0095-1137/03/\$08.00+0 DOI: 10.1128/JCM.41.1.261–266.2003  
 Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Vol. 41, No. 1

## Detection of *Mycoplasma genitalium* by PCR Amplification of the 16S rRNA Gene

Jørgen Skov Jensen,<sup>1\*</sup> Martin B. Borre,<sup>2</sup> and Birthe Dohn<sup>1</sup>

*Mycoplasma Laboratory, Department of Respiratory Infections, Meningitis, and Sexually Transmitted Infections,<sup>1</sup> and Laboratory of Molecular Biology,<sup>2</sup> Statens Serum Institut, DK-2300 Copenhagen S, Denmark*

Received 13 June 2002/Returned for modification 16 August 2002/Accepted 15 October 2002

In order to develop a species-specific PCR for the detection of *Mycoplasma genitalium*, the sequence of 1,490 bases of the 16S rRNA gene was determined for *M. genitalium* G37 (type strain) and four Danish isolates of *M. genitalium*. The sequences of the four Danish strains, mutually different with respect to their MgPa gene, were 100% homologous, although they carried a single common base substitution compared to the type strain. Among members of the *Mycoplasma pneumoniae* phylogenetic cluster, *M. genitalium* showed the most-prominent homology to the 16S rRNA sequence of *M. pneumoniae* (98% homology). From regions showing the least homology to the *M. pneumoniae* 16S rRNA gene sequence, primers were chosen to amplify DNA from *M. genitalium* only. Two sets of primers were selected for their ability to detect <10 to 50 *M. genitalium* genome copies without cross-reactions with *M. pneumoniae*. The performance of these primers was compared to the performance of two pairs of primers amplifying parts of the MgPa adhesin gene; 1,030 randomly selected specimens submitted for *Chlamydia trachomatis* culture were screened with one of the 16S rRNA gene primer sets. A total of 41 specimens were found to be positive for this gene; 40 of these could be confirmed by one of the MgPa primer sets, whereas the other MgPa primer set detected only 21 positive specimens out of 40. These results indicate that estimates of the prevalence of *M. genitalium* in various populations using MgPa PCR primers could be incorrectly low if the PCR primers are located in variable regions of the MgPa gene.

Two *Mycoplasma genitalium* strains were originally isolated in 1980 from the urogenital tracts of 2 of 13 men with non-gonococcal urethritis (NGU) (27). Despite repeated attempts with conventional culture techniques, no other urogenital isolates have been reported (21, 24). Using a cell-culture-based method, however, we succeeded in isolating four new strains from the urethras of male patients with NGU who were PCR positive for *M. genitalium* (11). *M. genitalium* and *Mycoplasma pneumoniae* share several structural properties, such as the flask shape and the terminal tip-like structure, and a significant antigenic relationship between the two mycoplasma species has hampered diagnostic serology (15; K. Lind, Letter, Lancet ii:1158–1159, 1982).

Because traditional diagnostic procedures for *M. genitalium* such as culture and serology have failed, other methods have been investigated. The development of a DNA probe provided some evidence for the presence of *M. genitalium* in the male urogenital tract (8), but data indicating that *M. genitalium* is a potential cause of NGU have only recently been demonstrated by the use of PCR (2, 9, 10, 13, 26).

*M. genitalium* strains recently isolated from Danish patients (11) show a significant degree of sequence diversity of the main adhesin (MgPa) gene. This variability has not yet been sufficiently characterized to determine the presence of conserved regions in the gene so that PCR primers covering all *M. genitalium* strains can be designed. Consequently, we decided to develop a species-specific PCR based on amplification of rRNA gene sequences.

(Part of this study was presented at the 10th International Congress of the International Organization for Mycoplasmatology, Bordeaux, France, July 1994. The abstract has been previously published [Int. Org. Mycoplastol. Lett. 3:332–333, 1994].)

### MATERIALS AND METHODS

**Organisms and growth conditions.** *M. genitalium* G-37<sup>T</sup> and four new Danish *M. genitalium* strains designated M 2298, M 2300, M 2321, and M 2341 were grown in modified Frits' FF medium (11) containing horse serum. The following species (strains) were grown in modified Hayflick's medium (15) and harvested by centrifugation in the late log phase: *M. pneumoniae* (FH<sup>T</sup>, Mac, M129-B8, M129-B170, and two clinical isolates), *Mycoplasma hominis* (PG21<sup>T</sup>, H34, H27, and three clinical isolates), *Mycoplasma solivorum* (PG20<sup>T</sup>), *Mycoplasma buccale* (CI1 2024<sup>T</sup>), *Mycoplasma oralis* (Parr and one clinical isolate), *Mycoplasma fermentans* (C<sup>T</sup> and S3b), *Mycoplasma faecium* (DC 333<sup>T</sup>), *Mycoplasma primatis* (Navel), *Mycoplasma pirum* (Z-cus), *Mycoplasma lipophilum* (Maby B<sup>T</sup>), *Mycoplasma hyoilectis* (GDL), *Mycoplasma arginini* (G230<sup>T</sup>), *Mycoplasma gallisepticum* (15302), *Acholeplasma laidlawii* (A<sup>T</sup>), and *Ureaplasma urealyticum* (serotypes I [F. Black 7] and VIII [F. Black 960]<sup>T</sup>). All were grown in U10C medium (20).

**DNA extraction.** DNA from *M. genitalium* G-37<sup>T</sup> and from the *M. pneumoniae* Mac strain was extracted with chloroform as previously described (12). DNA was quantified spectrophotometrically and by visual comparison after gel electrophoresis and ethidium bromide staining. DNA from the other mycoplasma species was released by resuspending the pellet from 2 ml of broth culture obtained after centrifugation at 30,000 × g for 15 min at 4°C in 100 µl of lysis buffer (10 mM Tris HCl [pH 8.0], 1 mM EDTA, 0.5% Tween 20, and 0.5% Nonidet P-40) containing proteinase K (200 µg/ml). The samples were incubated at 55°C for 30 min, the proteinase was inactivated at 94°C for 15 min, and the tubes were briefly centrifuged to collect condensation droplets. Clinical specimens were treated similarly, except that only 200 µl of the specimen was used; 10 µl was used for PCR.

**Sequence determination of the 16S rRNA gene.** Before we began development of the present assays, the 16S rRNA gene sequence was not available in public databases. Furthermore, four Danish *M. genitalium* strains were found to have hypervariable parts in their MgPa gene (18). Consequently, it was decided to determine the 16S rRNA gene sequence of the type strain G37 of *M. genitalium*.

\* Corresponding author. Mailing address: Mycoplasma Laboratory, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. Phone: 45 3268 3636. Fax: 45 3268 3152. E-mail: jsj@ssi.dk.

TABLE 1. Primers for PCR deduced from *M. genitalium* 16S rRNA gene sequence used in initial evaluation

Primer	Sequence:
MG16-45F	5' TAC ATG CAA GTC CAT CGG AAG TAG C
MG16-181R	5' ACC CTT GCA GGT CCT TTC AAC TTT A
MG16-252R	5' CGT CAT TGC CTT GGT AGG CCA
MG16-411R	5' TTC TTC CCA ATT AAA AGA ACT TTA CAA TCA A
MG16-437R	5' AAA CTC CAG CCA TTG CCT GCT AG
MG16-455R	5' GGT ACA GTC AAA CTC CAG CCA TTG
MG16-439F	5' GAA TGA CTC TAG CAG CCA ATG GCT G
MG16-636R	5' TCC AAA ACT CCC TAC CAC ACT CTA GAC TG
MG16-1117R	5' TCC TCC ATT TTA CTA TAG CAG TCT GCT TAA
MG16-1204F	5' CAA TGG CCA ATA CAA ACA GTA GCC AA
MG16-1301R	5' CTG ATT CGC GAT TAC TAG TGA TTC CAG
MG16-1428R	5' ACC GGT GCT ATC CTT GAC ATC CA
MG16-1421R	5' GTG CTA TCC TTG ACA TGC ACT TCC AA

\* Primer combinations MG16S-45F-MG16S-447R and MG16S-1204F-MG16S-1301R (underlined primers) were *M. genitalium* specific and used in the clinical evaluation.

as well as that of the four Danish strains in order to document the conserved nature of this gene. The 16S rRNA gene was amplified by PCR with primers binding to sequences conserved in most eubacteria. The PCR products were cloned in the pBluescript II SK vector (Stratagene, La Jolla, Calif.), and the sequencing reactions were performed using the Applied Biosystems cycle sequencing kit with dyc-dideoxy terminators. Sequences were read by an Applied Biosystems model 373A automatic sequencer. Both strands were sequenced from at least two clones from each strain.

Sequence analysis. Sequence data were analyzed with the Genetics Computer Group (Madison, Wis.) program package. The program Pileup was used for multiple sequence alignments.

Design of primers. Primers were selected from regions of the 16S rRNA gene showing the least sequence homology with the corresponding *M. pneumoniae* sequence. Since the two sequences were very similar, a maximum of three mismatches could be incorporated in each primer. Care was taken to avoid primers having a 3'-terminal T (14). The primers were examined for melting temperature ( $T_m$ ), secondary structure, and tendency to primer-dimer formation using the Oligo primer analysis software (version 4.0; MedProbe, Oslo, Norway). Three forward and 10 reverse primers with predicted  $T_m$  between 58.3 and 60.2°C (Table 1) were selected, allowing for 17 possible combinations. Eleven combinations were examined for their limit of detection (LOD) with purified *M. genitalium* DNA and for their specificity with *M. pneumoniae* DNA, corresponding to 3,500 copies and a pool of urogenital specimens PCR negative for *M. genitalium*.

PCR assay. The primer combinations were screened under the following conditions. A final reaction volume of 100  $\mu$ l containing 1  $\times$  PCR buffer (Super *Taq*; HT Biotechnology, Cambridge, United Kingdom) (10 mM Tris-HCl [pH 9.0], 50 mM KCl, 0.01% [wt/vol] gelatin, 0.1% Triton X-100) with 1.5 mM MgCl<sub>2</sub>; a 0.4  $\mu$ M concentration of each primer; a 125  $\mu$ M concentration (each) of dATP, dGTP, and dCTP; and 250  $\mu$ M dUTP. After preheating to 80°C (hot start) (3) 2 U of *Taq* DNA polymerase (Amplifying; Perkin-Elmer, Alameda, Denmark) diluted in 10  $\mu$ l of 1  $\times$  reaction buffer (withheld from the master mix) was added to initiate the reaction. Forty cycles were performed in an OmniGene Thermal Cycler (Hybaid Ltd., Teddington, United Kingdom), each consisting of a 94°C 30-s denaturation, a 55°C 30-s annealing, and a 72°C 1-min extension. Amplicons were visualized after electrophoresis on 2% agarose gels, which were stained with ethidium bromide and examined by UV transillumination.

The optimized assay using primers MG16-45F and MG16-447R was performed as described above except that the MgCl<sub>2</sub> concentration was 2.0 mM and that 40 two-step cycles were performed, each consisting of 94°C for 30 s and 60° for 60 s. The optimized MG16-1204F-MG16-1301R assay used 2.5 mM MgCl<sub>2</sub>, and 50 cycles of 94°C for 30 s and 58°C for 60 s were performed. The MgPa-476-MgPa-903 assay previously described (13) was slightly modified, as 1 U of Super *Taq* polymerase (HT Technology) was used and 40 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 60 s were performed. The MgPa-1-MgPa-3 assay (12) was also slightly modified by running 40 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 60 s with the reaction components described above except that the dUTP was replaced with dTTP at 125  $\mu$ M and the MgCl<sub>2</sub> concentration was 3.5 mM.

Construction of IPC for inhibition. In order to detect the presence of *Taq* DNA polymerase inhibitors or suboptimal reaction conditions, an internal pro-

cess control (IPC) was constructed. Primers amplifying parts of the phage lambda genome were selected based on the following criteria: (i) amplicon size at least 100 bp longer than the specific *M. genitalium* rRNA gene amplicon in order to allow preferential amplification of the rRNA gene amplicon, (ii) lack of secondary structure and primer-primer interaction as determined by the Gene Runner program (Hastings Software, Inc., Hastings, N.Y.), and (iii) a high  $T_m$  in order to render the IPC less efficient to amplify than the rRNA gene amplicon.

The primers included the sequence of each of the rRNA gene primers added to the 5' end of the corresponding lambda primer (5' TACATGCAA GTCGAT CGGAAGTAGCCCTGACGGTTCTAAC and 5' AAACCTCCAGGCCATTGCCT CCTAGGACATACGGAAATAC; sequence in boldface type corresponds to the phage lambda sequence at positions 13663 to 13677 and positions 14266 to 14280, respectively). PCR products thus containing the binding sites of the rRNA gene primers were obtained by amplification of 1 ng of purified lambda DNA with an annealing temperature of 40°C. After gel purification of the amplicon, a 10-fold titration was performed, and the dilution of the IPC producing no increase in the detection limit of purified *M. genitalium* DNA was used in the assay.

MTT-based hybridization assay. Amplicons produced with primers MG16S-45F-MG16S-447R were labeled with digoxigenin (DIG) during PCR by addition of DIG-11-dUTP to the master mix. The reaction components and cycling conditions were as described above, except that the reaction mixture contained a 62.5  $\mu$ M concentration (each) of dATP, dGTP, and dCTP; 125  $\mu$ M dUTP; 0.4  $\mu$ M DIG-11-dUTP; and 10  $\mu$ l of the appropriate dilution of IPC. After PCR, 5  $\mu$ l of the reaction products was added to wells of a heat-stable Microtiter plate (MTP) each containing 100  $\mu$ l of hybridization solution (100 mM NaCl, 10 mM Tris-HCl [pH 8.0], 5 mM EDTA, and 20 pM biotinylated probe MG16S-240 Bio [5' Bio-C-Bio-C-Bio-TTC GTC GGG TAA TGC CC]). The MTP was sealed with tape and placed in a 96-well combi thermal reactor TR2 (Hybaid) and subjected to a 2-min 95°C denaturation and 10 min 55°C hybridization. MaxiSorp MTPs (Nunc, Roskilde Denmark) were coated overnight at 4°C with streptavidin (5  $\mu$ g/ml; Sigma, St. Louis, Mo.) in carbonate buffer, pH 9.6. The wells were blocked for 15 min with 1% blocking reagent (Boehringer Mannheim) in phosphate-buffered saline, pH 7.4, with 0.05% Tween 20 (PBST) prepared as a 1:10 dilution of 10% blocking reagent dissolved in maleic acid buffer, as described by the manufacturer. Hybrids were collected for 30 min at 37°C. After capture, three washes with PBST were performed, and the bound hybrids were detected by incubation at 37°C for 30 min with peroxidase-conjugated sheep anti-DIG immunoglobulin G Fab fragments (0.6 U/ml; Boehringer Mannheim) diluted in PBST with 1% blocking reagent. After three additional washes with PBST the hybrids were visualized with 1,2-phenylenediamine-hydrochloride (KemEnTec, Copenhagen, Denmark) in citrate buffer pI 5.0. The reactions were stopped by addition of H<sub>2</sub>SO<sub>4</sub>, and the  $A_{450}$  was read in an ELISA reader (Molecular Devices, Menlo Park, Calif.). *M. pneumoniae* 16S rRNA gene amplicon produced by low-stringency PCR was included as specificity control.

Precautions to avoid PCR product carryover. Strict physical separation between PCR setup and analysis laboratories was maintained as previously described (13). Sterile filter tips (ART; SDS, Falkenberg, Sweden) were used in all manipulations with the samples. All surfaces in the PCR setup laboratory were regularly wiped with a 4% Diversol solution containing hypochlorite (19) and exposed to UV light between sessions with the purpose of destroying contaminating DNA.

Positive controls had low copy numbers, containing 10 and 100 genome copies of *M. genitalium*, respectively. At least two negative controls were included in each run. All *M. genitalium* 16S rRNA gene PCRs were performed with dUTP instead of dTTP, allowing for enzymatic prevention of PCR product carryover with uracil-N-glycosylase (16). Uracil-N-glycosylase was not used, however, since no carryover was observed.

Clinical specimens. A total of 1,030 samples from 730 patients were randomly chosen from specimens submitted for culture of *Chlamydia trachomatis*. The only available information about the patients was age, sex, and sampling site. A total of 885 urogenital specimens from 595 women were submitted (302 urethral, 581 cervical, and 2 vaginal specimens). The median age of women who had urogenital specimens submitted was 28 years (range, 2 to 58 years). The remaining 13 women had 16 specimens submitted (8 conjunctival, 2 respiratory, and 6 unknown). For the 120 male patients, 129 specimens were examined: 73 urethral swabs, 23 semen specimens, 18 conjunctival specimens, 8 respiratory specimens, and 7 other specimen. The median age of the 73 patients who had urethral specimens submitted was 27 years (range, 18 to 55 years). For two patients (two specimens) the sex and age were not known. Specimens were collected and transported in 2SP medium (12) and stored at -80°C until tested in the PCR.

VOL 41, 2003

## MYCOPLASMA GENITALIUM 16S rRNA GENE PCR 263




FIG. 1. LOD of MTP-based hybridization assay performed at 50°C with negative controls and various dilutions of *M. genitalium* amplicon. The biotinylated probe Mg16S-240 Bio was used at 10 pM. The negative control contained the IPC amplicon. Amplicons from *M. pneumoniae* were produced by low-stringency annealing of the primers.

## RESULTS

**Sequencing.** A total of 1,490 bp of the 16S rRNA gene was sequenced from *M. genitalium* G37 and each of the four Danish *M. genitalium* strains M2288, M2300, M2321, and M2341. The sequence of the *M. genitalium* G37 type strain has been deposited in GenBank under the accession number X77334. Compared to the G37 type strain, one nucleotide was different in Danish *M. genitalium* strains (a T instead of a C in position 1430). A significant homology of 98% with the *M. pneumoniae* 16S rRNA gene sequence was found; only 28 nucleotides differed in the *M. genitalium* G37 sequence, and only 29 nucleotides differed in the Danish strains.

**Design of primers.** Even if relatively relaxed criteria regarding general rules for design of primers were followed, only 13 different primers could be selected. These primers allowed for 17 possible combinations, but since some of the combinations would yield amplicons longer than 600 bp, only 11 combinations were actually tested. Two primer combinations were selected for further studies since they produced *M. genitalium* specific amplicons with a high efficiency even under the non-optimized screening conditions. The MG16-45F-MG16-447R primers were located in the V1 and V3 hypervariable regions, respectively, and produced the expected 427-bp amplicon, whereas the MG16-1204F-MG16-1301R primers were in the V8 region and outside defined variable regions, respectively. The 124-bp amplicon produced by the 1204-1301 primers was more difficult to detect by visual inspection of ethidium bromide-stained agarose gels; hence, the MG16-45F-MG16-447R primers were selected for the primary assay.

**LOD of assays.** Both primer sets had a LOD corresponding to <5 fg, equivalent to approximately six genome copies, when visual inspection of ethidium bromide-stained agarose gels was used for detection. The MTP-based hybridization assay did not improve the LOD, when purified DNA was tested; however, very faint bands in clinical specimens could be clearly positive in the hybridization assay. *M. genitalium* 16S rRNA gene PCR products visible by gel electrophoresis showed optical density (OD) readings of >0.5, whereas a large amount of *M. pneumoniae* 16S rRNA gene amplicon produced by low-stringency PCR showed OD readings of <0.05 (Fig. 1). The LOD was not

increased when the *M. genitalium* DNA was added to clinical specimens PCR negative for *M. genitalium* (Fig. 2).

**Specificity.** The hot-start procedure was found to be crucial for the specificity of amplification; >10<sup>3</sup> copies of *M. pneumoniae* DNA produced faint bands with the MG16-45F-MG16-447R primer set without hot start, whereas 10<sup>3</sup> copies of *M. pneumoniae* DNA gave negative results when the hot-start procedure was used. The effect of hot start could also be shown in a recent modification of the protocol, where the Amplitaq was substituted with 2 U of Platinum Tag (Invitrogen, Tåstrup, Denmark). Furthermore, the specificity of the assay was ensured by the hybridization step, since even large amounts of *M. pneumoniae* 16S amplicon produced by decreasing the annealing temperature to 40°C did not hybridize with the internal probe. None of the other mollicutes tested gave rise to unspecific amplification.

The MG16-1204F-MG16-1301R primer set cross-reacted with DNA from *M. gallisepticum* even when the hot-start procedure was applied. This cross-reaction was not considered to be important since this species has never been isolated from humans. Due to the short sequence between the primers with only a single base substitution between the *M. genitalium*, the *M. pneumoniae*, and the *M. gallisepticum* sequences, respectively, construction of an *M. genitalium*-specific probe was not attempted. No amplification was observed when a pool of *M. genitalium*-negative urogenital specimens used in the initial screening was tested. However, when the specificity evaluation was extended with a larger number of clinical specimens, amplicons with the same length as the positive control appeared in some of the urogenital specimens showing negative reactions both with the MG16-45F-MG16-447R and the MgPa-1-MgPa-3 primer sets. Consequently, the MG16-1204F-MG16-1301R primer set was not used for further clinical studies.

**IPC for inhibition.** The addition of approximately 10- to 50-fold the detection limit of the IPC produced the expected 666-bp fragment without increasing the LOD as shown in Fig. 2. As expected, preferential amplification of the shorter 16S rRNA gene amplicon occurred, resulting in the absence of the IPC from specimens with high amounts of *M. genitalium* DNA. It has been found that approximately 5% of clinical specimens contain inhibitors. No correlation as to the type of specimen has been shown, and in most specimens, the IPC can be amplified after a 1:2 or a 1:10 dilution of the specimen.




FIG. 2. Ethidium bromide-stained agarose gel showing the LOD of the *M. genitalium* 16S rRNA gene PCR and the effect of addition of the IPC and human DNA. Lane 1, 100-bp marker (Pharmacia); lane 2, ~500 genome copies of *M. genitalium* DNA; lane 3, ~50 genome copies of *M. genitalium* DNA; lane 4, ~5 genome copies of *M. genitalium* DNA; lane 5, negative control; lanes 6 to 9, same as lanes 2 to 5 but with addition of IPC; lanes 10 to 13, same as lanes 2 to 5 but with addition of IPC and 10 μl of clinical urogenital specimen.

**MTP-based hybridization assay.** The optimal concentration of the biotinylated probe was found to be crucial for the performance of the MTP-based hybridization assay, since the OD value dropped significantly after two- to fourfold dilution from the optimal concentration. The optimal concentration of the probe had to be determined for each new batch of probe, since differences were observed. The optimal hybridization temperature appeared to be of less importance since the OD of the *M. pneumoniae* amplicon control remained <0.05 even at 40°C.

**Clinical specimens.** (i) **Urogenital specimens from women.** Among the specimens from 595 women for whom urogenital specimens were submitted for *C. trachomatis* culture, *M. genitalium* was found in 27 (4.5%). For comparison, *C. trachomatis* was detected by PCR in 34 (5.6%). The median age of those positive for *M. genitalium* was 25 years (range, 17 to 56 years) but not statistically different from the age of the women tested (median age, 28 years). Patients with a positive *C. trachomatis* PCR were significantly younger (median age, 22 years; range, 17 to 37 years) than all women tested. No woman was positive at the same time for *M. genitalium* and *C. trachomatis*. Nineteen women PCR positive for *M. genitalium* had both a urethral and a cervical specimen submitted for *C. trachomatis* culture. Nine (47%) were PCR positive for *M. genitalium* in both specimens, whereas seven (41%) were positive in the cervical specimen only and three (16%) were positive in the urethral specimen only. Thus, the sensitivity for urethral specimens was 63% (12 of 19), and that for cervical specimens was 84% (16 of 19).

(ii) **Urogenital specimens from men.** Among the specimens from 73 men for whom urethral specimens were submitted for *C. trachomatis* culture, 7 (9.6%) were positive by PCR for *M. genitalium*. Ten (13.7%) were positive for *C. trachomatis* by PCR, but no specimen was positive for both organisms. None of the 23 semen specimens were PCR positive for *M. genitalium*.

(iii) **Other clinical specimens.** *M. genitalium* was not detected in any of the 49 extragenital specimens.

**Comparison between the *M. genitalium* 16S rRNA gene PCR and MgPa PCR.** The 41 specimens positive in the *M. genitalium* 16S rRNA gene PCR were subjected to PCR with the MgPa-1-MgPa-3 and the MgPa-476-MgPa-903 primer sets. In the MgPa-1-MgPa-3 assay, 40 of the positive specimens could be confirmed, whereas only 21 out of 40 available 16S rRNA gene PCR-positive specimens were also positive in the MgPa-476-MgPa-903 PCR assay. The urethral and the cervical swabs of eight women were both positive with the *M. genitalium* 16S rRNA gene PCR. When the urethral and cervical swabs of these women were examined with the MgPa-476-MgPa-903 primer set, the results for two women were concordant positive, the results for one woman were concordant negative, and the results for five women were discrepant.

## DISCUSSION

In recent years, DNA amplification techniques with PCR for *M. genitalium* have been introduced. By using these methods several studies have demonstrated an association between *M. genitalium* and NGU in males (2, 9, 10, 13, 25, 26; T. Deguchi, H. Komeda, M. Yasuda, K. Tada, H. Iwata, M. Asano, T. Ezaki, and Y. Kawada, Letter, Int. J. STD AIDS 6:144-145, 1995). Also, *M. genitalium* has been proposed to be involved in

cervicitis (28) and endometritis in females (4). At present, only a few studies have compared the efficiency of different PCR assays on clinical specimens (5, 13). Deguchi et al. (5) found results obtained with the MgPa-1-MgPa-3 primer set to be identical to those found with the primers described by Palmer et al. (17). This comparison was very important, since the majority of clinical studies have used one of these two assays. However, only 18 positive specimens were compared. We have previously found that the part of the MgPa gene amplified by the MgPa-1-MgPa-3 primer set contained mutations resulting in different restriction fragment length polymorphisms (12). Later, we observed that the amount of amplicons produced with the MgPa-1-MgPa-3 primer set compared with that produced with the MgPa-476-MgPa-903 primer set from patients enrolled in a clinical study of NGU was extremely variable. Furthermore, the sequence amplified with the MgPa-476-MgPa-903 primers revealed remarkable variation when subjected to restriction enzymic analysis (13). Despite this variation, a complete agreement between the two assays was found.

These observations led us to speculate whether the MgPa gene was an optimal target for a diagnostic PCR assay, and therefore, the 16S rRNA gene was selected as the target for development of a new assay. At that time, the sequence of the *M. genitalium* G37 16S rRNA gene was not available, and, furthermore, it was felt to be important to assure that the newly isolated *M. genitalium* strains had the same sequence as the type strain of *M. genitalium*. Consequently, the 16S rRNA gene sequences of five different strains were obtained. Only one nucleotide was found to differ between the *M. genitalium* G37 and the four Danish *M. genitalium* strains. The *M. genitalium* G37 16S rRNA gene sequence was later shown to be identical to that available from the genome sequence (6). Whether the single-nucleotide difference found among the Danish strains reflects geographical differences remains to be determined.

The two 16S rRNA gene primer combinations selected for further evaluation had an equal LOD when evaluated on dilutions of purified *M. genitalium* DNA, both alone and in simulated positive specimens. Using the hot-start protocol both primer sets were specific, when tested with *M. pneumoniae* DNA. A range of other mollicutes was tested to assure the specificity. Only DNA from *M. gallisepticum* cross-reacted in the MG16-1204F-MG16-1301R assay, even when the hot-start procedure was applied, but this was not regarded as a significant problem, since this species is not expected to be found in humans. Initially, a pool of *M. genitalium* MgPa PCR negative specimens were used for negative controls and for preparation of simulated positive specimens. No positive reactions were detected in the pooled specimens with the 16S PCRs. However, when individual clinical specimens were tested in the MG16-1204F-MG16-1301R assay sporadic positive reactions, which could not be confirmed with other primer sets, were observed. Therefore, these primers could not be recommended for use without an internal probe or confirmation with another PCR assay.

The MTP-based hybridization assay improved the specificity against *M. pneumoniae* since amplicons produced by low-stringency annealing were consistently negative even though only two nucleotides differed between the *M. genitalium* and the *M. pneumoniae* sequences. The PCR assay was adjusted to detect

VOL. 41, 2003

## MYCOPLASMA GENITALIUM 16S rRNA GENE PCR 265

very few genome copies during the amplification. This allowed the rapid detection of the specific product and the internal processing control by agarose gel electrophoresis. The MTP hybridization assay did not add additional sensitivity, and in a routine screening setting, only those specimens positive by gel electrophoresis would need hybridization in order to keep the specificity high. Many authors argue that gel electrophoresis is unsuitable for large-scale amplicon detection. In our hands, however, gel electrophoresis was found to be very time- and cost-efficient, since the result of 35 clinical specimens can be recorded within 30 min after completion of the PCR. On the other hand, the objective reading of a spectrophotometer and the possibility of automation are important advantages of the MTP-based hybridization assay.

The MG16-45F-MG16-447R primer set was not evaluated on many nonurogenital specimens during this study. *M. pneumoniae* has been reported in a few publications to be present in the urogenital tract (7, 23), and *M. genitalium* has been detected in respiratory tract specimens (1). Therefore, the mere detection of an amplicon on agarose gel electrophoresis should not be taken as evidence of an *M. genitalium* infection without a hybridization step or some kind of confirmatory PCR assay. For a confirmatory assay, the results of the present study clearly indicate that the MgPa-1-MgPa-3 primers are the best alternative primers of those tested. The single specimen positive only by the MG16-45F-MG16-447R primer set, could not be confirmed by any of the other primer sets, and therefore, it seems likely that it was a false positive in that assay.

The discrepancy between the low clinical sensitivity of the MgPa-476-MgPa-903 primer set found in the present study and the good agreement between the two MgPa-based assays in a previous study could be explained by the slightly changed reaction conditions used in this study. We increased the annealing temperature to 55 from 50°C, and the number of cycles was decreased from 50 to 40. These changes were justified by experiments using dilution series of *M. genitalium* G37 DNA, where it was found that the SuperTaq enzyme produced a significantly higher yield of amplicon than the AmpliTaq used in the original assay. These observations emphasize the importance of careful evaluations of PCR assays, whenever reaction parameters are changed. Due to lack of sample material, attempts to run the discrepant samples with the original protocol could not be undertaken. The fact that five of eight paired urethral and cervical specimens positive in the *M. genitalium* 16S rRNA gene PCR showed discrepant results in the MgPa-476-MgPa-903 assay indicates that the decreased clinical sensitivity could be due to a strain-dependent relative lack of sensitivity caused by sequence variation.

One 16S rRNA gene PCR assay has been published previously (22), but its application on clinical specimens has not been reported. The LOD was stated to be 1,000 *M. genitalium* cells, which is insufficient for clinical diagnostic work. Recently, a TaqMan real-time PCR assay based on amplification of the *M. genitalium* 16S rRNA gene was published (29). The LOD was reported to be 10 copies/reaction, which is marginally higher than that of the present assay. However, since external reference standards are not available, a head-to-head comparison between assays would be needed to determine the clinical sensitivity.

*M. genitalium* was found only in the urogenital specimens

examined both from men and women. The rate of positive findings was significantly higher in men than in women; however, this could easily be explained by the different healthcare-seeking behavior of men and women and by the different criteria for taking a specimen for *C. trachomatis* testing. Symptomatic men are more likely to be examined since screening among asymptomatic men is less widely used than screening among asymptomatic women. A corresponding higher proportion of *C. trachomatis* positive men further substantiate this explanation.

In both men and women, the rate of detection of *M. genitalium* was only slightly lower than that of *C. trachomatis*—4.5% compared to 5.6% in women and 9.6% compared to 13.7% in men—and the two organisms were not detected in the same patients, indicating that they may act as separate causes of urogenital tract illness. This is in agreement with most clinical studies published (2, 9, 10, 13, 25, 26; Deguchi et al., letter).

In conclusion, the PCR assay presented here could be a valuable supplement to the MgPa-based assays most widely used (12, 17), which appear to have a comparable performance. On the other hand, the results also demonstrate that other MgPa gene-based assays should be carefully evaluated before they can be used with confidence.

## REFERENCES

1. Baseman, J. B., S. F. Dlin, J. G. Tully, and D. L. Rose. 1988. Isolation and characterization of *Mycoplasma genitalium* strains from the human respiratory tract. *J. Clin. Microbiol.* 26:2266-2269.
2. Björnerius, E., P. Liebrink, and J. S. Jensen. 2000. *Mycoplasma genitalium* in non-gonococcal urethritis—a study in Swedish male STD patients. *Int. J. STD AIDS* 11:292-296.
3. Chou, Q., M. Russell, D. E. Birch, J. Raymond, and W. Bloch. 1992. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications. *Nucleic Acids Res.* 20:1717-1723.
4. Cohen, C. R., L. E. Manhart, E. A. Burkus, S. Astete, R. C. Brumham, K. K. Holmes, S. K. Sinel, J. J. Bwayo, and P. A. Totten. 2002. Association between *Mycoplasma genitalium* and acute endometritis. *Lancet* 359:763-766.
5. Deguchi, T., C. B. Gilroy, and D. Taylor-Robinson. 1993. Comparison of two PCR-based assays for detecting *Mycoplasma genitalium* in clinical specimens. *Eur. J. Clin. Microbiol. Infect. Dis.* 14:629-631.
6. Fraser, C. M., J. D. Gwynne, O. White, M. D. Adams, R. A. Clayton, R. D. Fleischmann, C. J. Bult, A. R. Kerlavage, G. Sutton, J. M. Kelley, et al. 1995. The minimal gene complement of *Mycoplasma genitalium*. *Science* 270:397-403.
7. Goulet, M., R. Dulhr, J. G. Tully, G. Billowes, and S. Kawajiya. 1995. Isolation of *Mycoplasma pneumoniae* from the human urogenital tract. *J. Clin. Microbiol.* 33:2825-2825.
8. Hooton, T. M., M. C. Roberts, P. L. Roberts, K. K. Holmes, W. E. Stamm, and G. E. Kenny. 1988. Prevalence of *Mycoplasma genitalium* determined by DNA probe in men with urethritis. *Lancet* i:266-268.
9. Horner, P., J. C. B. Gilroy, B. J. Thomas, R. O. Naidoo, and D. Taylor-Robinson. 1993. Association of *Mycoplasma genitalium* with acute non-gonococcal urethritis. *Lancet* 342:582-585.
10. Jaurie, M., F. Lassap, I. Casin, P. Crillot, C. Scieux, A. Zavarce, C. Chastang, A. Blanchi, and P. Morel. 1995. Male urethritis with and without discharge: a clinical and microbiological study. *Sex. Transm. Dis.* 22:244-252.
11. Jensen, J. S., H. T. Hansen, and K. Lind. 1996. Isolation of *Mycoplasma genitalium* strains from the male urethra. *J. Clin. Microbiol.* 34:286-291.
12. Jensen, J. S., S. A. Uldum, J. Sondergaard-Andersen, J. Yunst, and K. Lind. 1991. Polymerase chain reaction for detection of *Mycoplasma genitalium* in clinical samples. *J. Clin. Microbiol.* 29:46-50.
13. Jensen, J. S., R. Ørsund, B. Dohn, S. Ulbom, A. M. Worm, and K. Lind. 1993. *Mycoplasma genitalium*: a cause of male urethritis? *Genitourin. Med.* 69: 265-269.
14. Kwoh, S., D. E. Kellogg, N. McKinney, D. Spasic, L. Godin, C. Levenson, and J. J. Spinks. 1990. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. *Nucleic Acids Res.* 18:999-1005.
15. Lind, K., B. Ø. Lindhardt, H. J. Schüttler, J. Blom, and C. Christiansen. 1984. Serological cross-reactions between *Mycoplasma genitalium* and *Mycoplasma pneumoniae*. *J. Clin. Microbiol.* 20:1036-1043.
16. Longo, M., C. M. S. Berninger, and J. L. Hartley. 1990. Use of uracil DNA

266 JENSEN ET AL.

J. CLIN. MICROBIOL.

glycosylase to control carry-over contamination in polymerase chain reactions. *Gene* 93:125–128.

17. Palmer, H. M., C. B. Gilroy, P. M. Furr, and D. Taylor-Robinson. 1991. Development and evaluation of the polymerase chain reaction to detect *Mycoplasma genitalium*. *FEMS Microbiol. Lett.* 61:199–203.
18. Peterson, S. N., C. C. Bailey, J. S. Jensen, M. B. Borre, E. S. King, K. F. Bott, and C. A. Hutchison. 1995. Characterization of repetitive DNA in the *Mycoplasma genitalium* genome: possible role in the generation of antigenic variation. *Proc. Natl. Acad. Sci. USA* 92:11829–11833.
19. Prince, A. M., and L. Andrus. 1992. PCR—how to kill unwanted DNA. *BioTechniques* 12:358.
20. Razin, S., and J. G. Tully. 1983. Methods in mycoplasmology, vol. 1. Mycoplasma characterization. Academic Press, Inc., New York, N.Y.
21. Samra, Z., M. Borin, Y. Bukowsky, Y. Lipsitz, and D. Sempolinsky. 1988. Non-occurrence of *Mycoplasma genitalium* in clinical specimens. *Eur. J. Clin. Microbiol. Infect. Dis.* 7:49–51.
22. Sasaki, Y., M. Shintani, T. Shimada, H. Watanabe, and T. Sasaki. 1992. Detection and Discrimination of *Mycoplasma pneumoniae* and *Mycoplasma genitalium* by the *in vitro* DNA amplification. *Microbiol. Immunol.* 36:21–27.
23. Sharma, S., R. Brousseau, and S. Kasaiya. 1998. Detection and confirmation of *Mycoplasma pneumoniae* in urogenital specimens by PCR. *J. Clin. Microbiol.* 36:277–280.
24. Taylor-Robinson, D., P. M. Furr, and N. F. Illana. 1985. Microbiological and serological study of non-gonococcal urethritis with special reference to *Mycoplasma genitalium*. *Centaurin. Med.* 61:319–324.
25. Taylor-Robinson, D., J. S. Jensen, G. Fehler, F. Radke, and R. C. Ballard. 2002. Observations on the microbiology of urethritis in black South African men. *Int. J. STD AIDS* 13:323–325.
26. Totman, P. A., M. A. Schwartz, K. E. Sjostrom, G. E. Kenny, H. E. Handelsfield, J. B. Weiss, and W. L. Whittington. 2001. Association of *Mycoplasma genitalium* with nongonococcal urethritis in heterosexual men. *J. Infect. Dis.* 183:269–276.
27. Tully, J. G., D. Taylor-Robinson, R. M. Cole, and D. L. Rose. 1981. A newly discovered mycoplasma in the human urogenital tract. *Lancet* i:1288–1291.
28. Uno, M., T. Deguchi, H. Komeda, M. Hayasaka, M. Iida, M. Nagatani, and Y. Kawada. 1997. *Mycoplasma genitalium* in the cervix of Japanese women. *Sex. Transm. Dis.* 24:284–286.
29. Yashida, T., T. Deguchi, M. Ito, S. Maeda, M. Tamaki, and H. Ishiko. 2002. Quantitative detection of *Mycoplasma genitalium* from first-pass urine of men with urethritis and asymptomatic men by real-time PCR. *J. Clin. Microbiol.* 40:1451–1455.